These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24373912)

  • 1. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.
    Sheikh AR; Westley I; Sallustio B; Horowitz JD; Beltrame JF
    Heart Lung Circ; 2014 Jun; 23(6):e149-51. PubMed ID: 24373912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Terbinafine : Relevant drug interactions and their management].
    Dürrbeck A; Nenoff P
    Hautarzt; 2016 Sep; 67(9):718-23. PubMed ID: 27474731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of serotonin re-uptake inhibitors with perhexiline.
    Alderman CP; Hundertmark JD; Soetratma TW
    Aust N Z J Psychiatry; 1997 Aug; 31(4):601-3. PubMed ID: 9272272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
    Jones TE; Morris RG; Horowitz JD
    Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new antifungal preparation Lamisil (terbinafine)].
    Eksp Klin Farmakol; 1993; 56(5):69-79. PubMed ID: 8312820
    [No Abstract]   [Full Text] [Related]  

  • 7. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
    Davies BJ; Coller JK; James HM; Gillis D; Somogyi AA; Horowitz JD; Morris RG; Sallustio BC
    Br J Clin Pharmacol; 2004 Apr; 57(4):456-63. PubMed ID: 15025744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline.
    Castberg I; Helle J; Aamo TO
    Ther Drug Monit; 2005 Oct; 27(5):680-2. PubMed ID: 16175144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium.
    Chong CR; Drury NE; Licari G; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1485-91. PubMed ID: 26376650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between nortriptyline and terbinafine.
    Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
    Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses.
    Kienzler JL; Queille-Roussel C; Mugglestone C; Ortonne JP; Larnier C
    Curr Med Res Opin; 2007 Jun; 23(6):1293-302. PubMed ID: 17559730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
    Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Terbinafine and warfarin interaction].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 1999 May; 126(5):463. PubMed ID: 10434116
    [No Abstract]   [Full Text] [Related]  

  • 20. Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography.
    Davies BJ; Herbert MK; Culbert JA; Pyke SM; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):114-20. PubMed ID: 16434242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.